Antiva Biosciences
Latest round
- Series E
Last raised
- Apr 2023
Total raised
- $84M
Investors
- 17
About Antiva Biosciences
Antiva Biosciences, Inc. is focused on creating advanced treatments for cervical health issues caused by HPV.56 mn on April 24, 2023.Antiva Biosciences is dedicated to developing a topical antiviral treatment aimed at combating pre-cancerous cervical lesions caused by human papillomavirus (HPV). Their core product empowers women by providing a non-invasive, home-based management option for HPV infections, addressing a critical need for safer and less invasive treatment alternatives.Antiva Biosciences employs a direct-to-consumer business model for its antiviral treatments, facilitating access for patients. Their revenue generation structure may involve partnerships with healthcare providers and retail pharmacies to enhance distribution.In April 2023, Antiva Biosciences, Inc. The company plans to expand its market reach into new geographic regions, focusing on areas with significant demand for HPV-related health solutions.
Who invested in Antiva Biosciences
17 investors across 5 rounds
See all investors in Antiva Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Antiva Biosciences
Who invested in Antiva Biosciences?
Antiva Biosciences has 17 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Antiva Biosciences raised?
Antiva Biosciences has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Antiva Biosciences last raise money?
Antiva Biosciences's most recent round on record is a Series E, in Apr 2023.
What does Antiva Biosciences do?
Antiva Biosciences is a biotechnology company.
Where is Antiva Biosciences headquartered?
Antiva Biosciences is headquartered in Brisbane, US.
Which VCs invest in companies like Antiva Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Antiva Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Antiva Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.